Analysts' Actions: EMC, FFIV, WMS, CLX

CHANGE IN RATINGS, EPS

Abbott Laboratories (ABT) downgraded at JP Morgan from Overweight to Neutral. Valuation call, as the stock has outperformed its peers year-to-date.

Accenture (ACN) estimates lowered at Citigroup through 2012. Small adjustments due to negative FX moves. Maintain $66 price target and Buy rating.

Accretive Health (AH) rated new Buy at UBS. $29 price target. Riding healthcare tailwinds to address a large market opportunity.

Alexion Pharmaceuticals (ALXN) numbers raised at Oppenheimer to $74. Estimates also increased, as Solaris should continue to drive growth. Outperform rating.

AMC Networks (AMCX) rated new Sell at Stifel Nicolaus. Valuation call, based on a $30 price target.

Baxter (BAX) upgraded at JP Morgan from Neutral to Overweight. Sales growth should accelerate over the next several quarters.

Boston Scientific (BSX) upgraded at JP Morgan from Underweight to Neutral. Valuation call, as the stock is down 34% since last January. Company sports an attractive 13% free cash flow yield.

Bunge Limited (BG) upgraded at Citigroup from Hold to Buy. $88 price target. See significant value following the 24% decline over the past two months.

Clorox (CLX) upgraded at Caris from Below Average to Average. $66 price target. Stock is attractive, following the Icahn-related selloff.

Corn Products International (CPO) estimates, target cut at Citigroup.Shares of CPO now seen reaching $68. Estimates also lowered on FX headwinds. Maintain Buy rating.

Dollar Tree (DLTR) numbers increased at Morgan Stanley. DLTR estimates were raised through! 2014, M organ Stanley said. Company should continue to grow square footage and see better store traffic over the next several quarters. Overweight rating and new $86 price target.

EMC (EMC) target reduced at Morgan Stanley to $33. Macro weakness could hurt IT spending. In addition, the company is facing increased competition. Overweight rating.

F5 Networks (FFIV) rated new Hold at Jefferies. Valuation call, based on a $70 price target.

Freescale Semiconductor (FSL) estimates lowered at Credit Suisse through 2012. Company is seeing weaker industrial and networking demand. Outperform rating and $27 price target.

Gartner (IT) rated new Neutral at Goldman Sachs. $35 price target. Macro headwinds could hurt near-term growth.

Genesis Energy (GEL) upgraded at UBS from Neutral to Buy. $27 price target. Valuation call, along with strong financial metrics.

Holly Energy (HEP) upgraded at UBS from Neutral to Buy. $55 price target. Attractive valuation for stable business.

Hunstman (HUN) cut from Conviction Buy List at Goldman Sachs. Estimates also lowered, as the sector is facing lower demand and currency/commodity headwinds. New $14 price target.

Legg Mason (LM) numbers cut at Jefferies. Shares of LM now seen reaching $31. Estimates also reduced, given higher market volatility. Buy rating.

Maximus (MMS) rated new Market Outperform at JMP Securities. $41 price target. Company can continue to grow across the globe.

Precision Drilling (PDS) rated new Outperform at Credit Suisse. $16 price target. Canadian operations should drive ! growth o ver the next several quarters.

Riverbed Technology (RVBD) rated new Underperform at Jefferies. $15 price target. WAN optimization market should see decelerating growth.

Stryker (SYK) upgraded at JP Morgan to Overweight. Valuation call, as the stock is down 12% year-to-date.

Vera Bradley (VRA) rated new Buy at Jefferies. $50 price target. Company is still in the early stages of an attractive growth opportunity.

WMS Industries (WMS) downgraded at Sterne Agee from Buy to Neutral. $22 price target. Company lacks near-term catalysts.

Zimmer (ZMH) downgraded at JP Morgan to Neutral. Company will likely see slower growth in the coming quarters.

End of report.